|
Outcomes following preoperative chemoradiation +/- pazopanib in non-rhabdomyosarcoma soft tissue sarcoma (NRSTS): A report from Children's Oncology Group (COG) and NRG Oncology. |
| |
|
Consulting or Advisory Role - BioAtla |
Travel, Accommodations, Expenses - SpringWorks Therapeutics |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Adaptimmune; Bayer; Daiichi Sankyo; Epizyme |
Research Funding - Adaptimmune (Inst); Amgen (Inst); AstraZeneca (Inst); Exelixis (Inst); Immune Design (Inst); Iterion Therapeutics (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst) |
| |
|
|
Consulting or Advisory Role - Bayer |
| |
|
Patents, Royalties, Other Intellectual Property - I am a co-inventor on US patents 5641867, 6228837, 6734168, 9125959, 9339574, and 9839709, none of which have been under licensure or paid royalties in the last two years. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
Honoraria - Biomet; Daiichi Sankyo; Onclive; Onkos Surgical |
Travel, Accommodations, Expenses - Biomet; Daiichi Sankyo/Lilly |
| |
|
Research Funding - National Institute of Health (NIH)/National Clinical Trials Network (NCTN) |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Incyte (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Research Funding - Bayer (Inst); Bayer HealthCare Pharmacuticals (Inst); Loxo (Inst); Medpace (Inst) |